The EV/Exosome Field Is at an Inflection Point. BioThera Has the Infrastructure to Capitalize on It.

Extracellular vesicle technology is transitioning from academic science to commercial-scale skincare — and the manufacturing infrastructure to support that transition is the missing piece. BioThera has built it: a proprietary plant-derived EV biomanufacturing platform with a commercially launched dermocosmetic product operating at Technology Readiness Level (TRL) 7-8, in active dermatologist-led clinical evaluation, rigorous batch-level characterization, and a clear roadmap for scaling our dermocosmetic and EV-based skincare portfolio. We are raising pre-seed/seed capital, selectively, from partners who understand platform bets.

Request Investment Materials Learn About BioThera

View on Crunchbase

Round Stage

Pre-Seed / Seed

Status

Actively Raising

Investor Type

Strategic Only

Materials

Available Under NDA

The Case

Why EV Biomanufacturing?

Extracellular vesicles are poised to redefine the next generation of skincare. The bottleneck is not the science — it is the manufacturing infrastructure. That is what we are building.

A Defining EV Skincare Platform

EVs are a powerful biological delivery system uniquely suited to the skin — characterized, standardized, and engineered for performance. BioThera is not building a single product. We are building the plant-derived EV biomanufacturing platform that the dermocosmetic and EV-based skincare category requires.

The Infrastructure Gap

Scalable, standardized EV manufacturing is the critical missing piece preventing the EV skincare category from maturing. We are building that infrastructure with the rigour of a pharmaceutical-grade workflow and the velocity of a startup.

Regulatory-Efficient Path

Dermocosmetics provides a regulatory-efficient path to validate the platform in the real world — generating clinical evidence, real-world operational data, and proof points that compound across every additional EV-based skincare application we bring forward.

Current Status

Where We Are Today

Credential-forward. No financial projections disclosed publicly.

Health Canada Cosmetic Notification

Complete

Proprietary Technology

Proprietary technology with ongoing IP protection — details available under NDA

Complete

Clinical Evaluation

Active — multi-site, dermatologist partners, Ottawa

Active

Clinical Data Collection

Ongoing — patient outcomes, tolerability, and efficacy data accumulating across sites

Ongoing

Technology Readiness Level

TRL 7-8 — system prototype demonstrated in operational environment via active dermatologist-led clinical evaluation; manufacturing process complete and qualified under Health Canada Cosmetic Regulations.

TRL 7-8

Investor Inquiry

Are You the Right Partner?

We are raising selectively. We want investors who are aligned on the long-term vision, bring more than capital, and understand the EV biomanufacturing opportunity. Complete the form below — we will follow up if there is alignment.

First Name *

Last Name *

Email Address *

Organization / Fund *

Investor Type *

Typical Ticket Size *

Why BioThera? (optional but recommended)

Keep me updated with BioThera's newsletter — research insights, product news, and clinical updates. (Optional)

*I confirm that I am an accredited investor as defined under National Instrument 45-106 Prospectus Exemptions (Canada), or hold equivalent accredited/sophisticated investor status under the applicable securities laws of my jurisdiction.

*I consent to BioThera Solutions Inc. collecting and processing my personal information for investor relations purposes, as described in our Privacy Policy. Data is retained for a minimum of 24 months.

By submitting this form, you confirm that you are an accredited investor or equivalent qualified investor under the securities laws of your jurisdiction — including, as applicable, National Instrument 45-106 (Canada), Rule 501 of Regulation D under the Securities Act of 1933 (United States), or equivalent exemptions in your country of residence. This inquiry does not constitute a public offering of securities in any jurisdiction. Any investment will be made only pursuant to definitive offering documents under applicable exemptions from registration or prospectus requirements.

Investor Data Room

A dedicated investor portal with detailed materials — financials, IP overview, technical data packages, and team background — is available under NDA. Submit an inquiry above to request access.

Forward-Looking NoticeThis page contains forward-looking statements based on current expectations. Actual results may differ materially. Nothing on this page constitutes an offer to sell or solicitation of an offer to buy securities. Any offering will be conducted under applicable private placement exemptions.

This page is for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in any jurisdiction. Any offering of securities by BioThera Solutions Inc. will be conducted on a private placement basis pursuant to applicable exemptions — including the accredited investor exemption under National Instrument 45-106 (Canada), Rule 506 of Regulation D under the Securities Act of 1933 (United States), and equivalent private placement exemptions in other jurisdictions. Participation in any offering is restricted to accredited investors, qualified investors, or other persons eligible under applicable securities law exemptions in their respective jurisdiction. Forward-looking statements reflect current expectations and are subject to known and unknown risks, uncertainties, and assumptions that could cause actual results to differ materially. This communication does not constitute investment advice. Past performance is not indicative of future results.